Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti–complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of complement activation, (2) verify whether suc...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Noris, Marina, Galbusera, Miriam, Gastoldi, Sara, Macor, Paolo, Banterla, Federica, Bresin, Elena, Tripodo, Claudio, Bettoni, Serena, Donadelli, Roberta, Valoti, Elisabetta, Tedesco, Francesco, Amore, Alessandro, Coppo, Rosanna, Ruggenenti, Piero, Gotti, Eliana, Remuzzi, Giuseppe
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2014
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4162105/
https://ncbi.nlm.nih.gov/pubmed/25037630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-558296
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg